CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »
Among the state-of-the-art presentations on headache medicine at AHS 2025 (19-22 June, Minneapolis, USA), were latest real world data on the use of anti-CGRP therapies and their impact on public and clinician attitudes to migraine and its treatment.
Attitudes to migraine and the way it is discussed may be changing following the introduction of new treatments such as anti-CGRP therapies.1 An analysis of the impact of language guidelines from the Coalition for Headache and Migraine Patients (CHAMP) and the American Migraine Foundation (AMF)2 on stigmatising language in migraine-related social media posts has shown …
Read more »Further data supporting dual CGRP mAb/gepant therapy for migraine prevention in treatment-resistant patients comes from a small retrospective, real-world study of CGRP mAbs and gepants carried out through the University of Vermont Health Network, including data from January 1, 2020 through December 31, 2024.1 This follows previously reported results suggesting that dual therapy can reduce …
Read more »Preliminary data from a retrospective chart review of adolescents who were treated simultaneously with anti-CGRP agents and onabotulinumtoxinA for refractory headache have shown promising additive benefit compared to monotherapy. The results are from 55 patients with a median age of 16.4 years (IQR 15.5-16.9), treated at a US tertiary care paediatric headache clinic between 2020 …
Read more »Real-world data from health records of patients treated with anti-CGRP therapies for the first time at Jefferson Headache Center, Philadelphia, USA, between January 2018 and May 2025 have shown negligible effects on blood pressure during 12 months follow up compared with controls. Small effects on body mass index (BMI) were seen with some agents. Of …
Read more »Retrospective, real-world, patient-reported outcomes data support the use of intranasal zavegepant in acute migraine treatment. Of the 60 patients who had used intranasal zavegepant 10 mg at least twice (median nine doses) and were surveyed using the migraine treatment optimisation questionnaire-5 (MTOQ-5), 27 (45.0%) reported pain freedom within 2 hours of most attacks half the time …
Read more »CT-132, the app-based support tool that integrates multiple evidence-based behavioural techniques, including elements of cognitive behavioural therapy, has been shown to boost the efficacy of anti-CRGP therapies in patients with episodic migraine. In the 12-week, Phase 3 bridging study, Reduction in Monthly Migraine Days (ReMMiD-C), CT-132 reduced monthly migraine days (MMDs) compared to a sham …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
